279 related articles for article (PubMed ID: 30289453)
1. Glycoengineered antibodies: towards the next-generation of immunotherapeutics.
Mastrangeli R; Palinsky W; Bierau H
Glycobiology; 2019 Mar; 29(3):199-210. PubMed ID: 30289453
[TBL] [Abstract][Full Text] [Related]
2. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
3. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
4. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
5. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.
Beck A; Wagner-Rousset E; Bussat MC; Lokteff M; Klinguer-Hamour C; Haeuw JF; Goetsch L; Wurch T; Van Dorsselaer A; Corvaïa N
Curr Pharm Biotechnol; 2008 Dec; 9(6):482-501. PubMed ID: 19075687
[TBL] [Abstract][Full Text] [Related]
6. Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody.
Falck D; Thomann M; Lechmann M; Koeleman CAM; Malik S; Jany C; Wuhrer M; Reusch D
MAbs; 2021; 13(1):1865596. PubMed ID: 33382957
[TBL] [Abstract][Full Text] [Related]
7. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.
Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS
Front Immunol; 2017; 8():1554. PubMed ID: 29181010
[TBL] [Abstract][Full Text] [Related]
8. Functional Role of Carbohydrate Residues in Human Immunoglobulin G and Therapeutic Monoclonal Antibodies.
Dorokhov YL; Sheshukova EV; Kosobokova EN; Shindyapina AV; Kosorukov VS; Komarova TV
Biochemistry (Mosc); 2016 Aug; 81(8):835-57. PubMed ID: 27677552
[TBL] [Abstract][Full Text] [Related]
9. Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.
Liu CP; Tsai TI; Cheng T; Shivatare VS; Wu CY; Wu CY; Wong CH
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):720-725. PubMed ID: 29311294
[TBL] [Abstract][Full Text] [Related]
10. With or without sugar? (A)glycosylation of therapeutic antibodies.
Hristodorov D; Fischer R; Linden L
Mol Biotechnol; 2013 Jul; 54(3):1056-68. PubMed ID: 23097175
[TBL] [Abstract][Full Text] [Related]
11. Chemoenzymatic Glyco-engineering of Monoclonal Antibodies.
Giddens JP; Wang LX
Methods Mol Biol; 2015; 1321():375-87. PubMed ID: 26082235
[TBL] [Abstract][Full Text] [Related]
12. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function.
Popp O; Moser S; Zielonka J; Rüger P; Hansen S; Plöttner O
MAbs; 2018; 10(2):290-303. PubMed ID: 29173063
[TBL] [Abstract][Full Text] [Related]
13. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.
Higel F; Seidl A; Sörgel F; Friess W
Eur J Pharm Biopharm; 2016 Mar; 100():94-100. PubMed ID: 26775146
[TBL] [Abstract][Full Text] [Related]
14. Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments.
Jez J; Antes B; Castilho A; Kainer M; Wiederkum S; Grass J; Rüker F; Woisetschläger M; Steinkellner H
J Biol Chem; 2012 Jul; 287(29):24313-9. PubMed ID: 22589538
[TBL] [Abstract][Full Text] [Related]
15. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
16. Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties.
Olovnikova NI; Ershler MA; Grigorieva OV; Petrov AV; Miterev GY
Biochemistry (Mosc); 2012 Aug; 77(8):925-33. PubMed ID: 22860915
[TBL] [Abstract][Full Text] [Related]
17. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
18. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
[TBL] [Abstract][Full Text] [Related]
19. Fc glycans of therapeutic antibodies as critical quality attributes.
Reusch D; Tejada ML
Glycobiology; 2015 Dec; 25(12):1325-34. PubMed ID: 26263923
[TBL] [Abstract][Full Text] [Related]
20. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
